Search results for: Adrian Towse
Filter search results
Spotlight on OHE: Recent Awards, Publications and Presentations
12 September 2012
…Valuing health at the end of life: An exploratory preference elicitation study. OHE Research Paper 11/06. London: Office of Health Economics. [2] Puig-Peiró, R., Mestre-Ferrandiz, J., MacDonald, F. and Towse,…
OHE Study on Pharmaceutical R&D Costs Released
3 December 2012
…use. These are essential both to encouraging R&D and ensuring that patients have the earliest access possible to life-changing therapies’. Contact: Jorge Mestre-Ferrandiz Download Mestre-Ferrandiz, J., Sussex, J. and Towse,…
R&D Cost Drivers to be Explained by OHE Expert
18 January 2013
…UCL at +44 (0)20 7679 4411 . Read the recent report: download Mestre-Ferrandiz, J., Sussex, J. and Towse, A. (2012) The R&D Cost of a New Medicine. London: Office of Health Economics….
New OHE Study Compares Decisions by Five HTA Agencies on Oncology Meds
31 January 2013
…HTA agencies sometimes reach different conclusions about the same medicines. The authors discuss possible reasons for these differences and offer recommendations for improving HTA processes. Shah, K.K., Mestre-Ferrandiz, J., Towse,…
Valuing Co-Dependent Medical Technologies: Improving Methods and Processes
23 April 2013
…information, please contact Martina Garau. See also: Garau, M., Towse, A., Garrison, L., Housman, L. and Ossa, D. (2012) Can and should value based pricing be applied to molecular diagnostics?…
Exploring the Link Between Health and Wealth in Government Decision Making
16 May 2013
…to address the barriers identified in order to ensure efficient priority setting within health and across public sectors. Download: Garau, M., Shah, K., Sharma, P. and Towse, A. (2013) Is…
Defining Innovation in Medicines and Transforming it into Value
3 July 2013
…here, and on Shah, K.K., Mestre-Ferrandiz, J., Towse, A. and Smythe, E.N. (2013) A review of health technology appraisals: case studies in oncology. International Journal of Technology Assessment in Health Care. 29(1),…
Critique of Research Proposing to Lower NICE’s Cost-per-QALY Threshold to £12,936
2 December 2013
…If these assumptions do not hold, then Claxton et al overestimate the success of PCTs in improving health and consequently underestimate the NICE threshold. [1] Download Barnsley, P., Towse, A., Schaffer,…
Biosimilars and HTA: Results of a Roundtable Discussion
9 April 2014
…J. & Towse, A., 2014. What is the role of HTA for biosimilars? Briefing, 54, London: Office of Health Economics. For other OHE publications on biosimilars, click here. For additional…